10.10.11
Results from an open label study of Vascazen, from Pivotal Therapeutics Inc., indicate significant and rapid improvement in participants' omega 3 blood levels after two weeks of supplementation.
The primary objective of the study was to assess the efficacy and safety of Vascazen, measuring participants' omega 3 blood levels at two-week intervals. The final results of the study indicate that four capsules per day of Vascazen, providing 3 grams per day of EPA and DHA, resulted in a rapid improvement in study participants' omega 3 blood levels. In addition to the positive results regarding Vascazen’s efficacy, it was also shown to be safe and well tolerated.
The study, conducted by Pivotal, offered results from the baseline Omega-Score assessment in 143 participants: 106 male and 37 female. Findings revealed that more than 84% of study participants' baseline omega 3 levels scored in the "moderate" to "very high risk" range with an average score of 3.4% (very high risk) with similar trends in both the male and female populations.
Findings showed significant and rapid improvement in participants' Omega-Score after two weeks with the baseline average of 3.4% (very high risk) increasing to 5.7% (moderate risk). Within four weeks, omega 3 blood levels increased to an average of 7.9% (low risk) with these levels maintained for the remainder of the study. For further information: www.pivotaltherapeutics.us
The primary objective of the study was to assess the efficacy and safety of Vascazen, measuring participants' omega 3 blood levels at two-week intervals. The final results of the study indicate that four capsules per day of Vascazen, providing 3 grams per day of EPA and DHA, resulted in a rapid improvement in study participants' omega 3 blood levels. In addition to the positive results regarding Vascazen’s efficacy, it was also shown to be safe and well tolerated.
The study, conducted by Pivotal, offered results from the baseline Omega-Score assessment in 143 participants: 106 male and 37 female. Findings revealed that more than 84% of study participants' baseline omega 3 levels scored in the "moderate" to "very high risk" range with an average score of 3.4% (very high risk) with similar trends in both the male and female populations.
Findings showed significant and rapid improvement in participants' Omega-Score after two weeks with the baseline average of 3.4% (very high risk) increasing to 5.7% (moderate risk). Within four weeks, omega 3 blood levels increased to an average of 7.9% (low risk) with these levels maintained for the remainder of the study. For further information: www.pivotaltherapeutics.us